Search

Your search keyword '"Fumiharu, Kimura"' showing total 3 results
Start Over Author "Fumiharu, Kimura" Journal journal of neuroimmunology
3 results on '"Fumiharu, Kimura"'

1. Neurologic disorders associated with anti-glutamic acid decarboxylase antibodies: A comparison of anti-GAD antibody titers and time-dependent changes between neurologic disease and type I diabetes mellitus

Author

Yuiko Inaba, Chiharu Tsutsumi, Toshiaki Hanafusa, Masamichi Date, Takafumi Hosokawa, Kiichi Unoda, Fumiharu Kimura, Hideto Nakajima, Yoshitsugu Nakamura, and Haruko Kitaoka

Subjects
0301 basic medicine, Adult, Male, endocrine system diseases, medicine.medical_treatment, Immunology, Glutamate decarboxylase, Autoantigens, 03 medical and health sciences, Epilepsy, 0302 clinical medicine, Autoimmune Diseases of the Nervous System, Immunology and Allergy, Medicine, Humans, Aged, Autoantibodies, Cerebellar ataxia, biology, business.industry, Glutamate Decarboxylase, Limbic encephalitis, nutritional and metabolic diseases, Immunotherapy, Middle Aged, medicine.disease, Titer, 030104 developmental biology, Diabetes Mellitus, Type 1, Neurology, biology.protein, Female, Neurology (clinical), medicine.symptom, Antibody, business, 030217 neurology & neurosurgery, Stiff person syndrome
Abstract

To determine clinical features of neurologic disorders associated with anti-glutamic acid decarboxylase antibodies (anti-GAD-Ab), we examined titers and time-dependent changes of anti-GAD-Ab. Six patients, stiff person syndrome (2), cerebellar ataxia (1), limbic encephalitis (1), epilepsy (1), brainstem encephalitis (1), were compared with 87 type I diabetes mellitus (T1DM) patients without neurologic disorders. Anti-GAD-Ab titers and index were higher in neurologic disorders than in T1DM, suggesting intrathecal antibody synthesis. Anti-GAD-Ab titers in T1DM decreased over time, whereas they remained high in neurologic disorders. Immunotherapy improved neurological disorders and anti-GAD-Ab titers and index provide clinically meaningful information about their diagnostic accuracy.

Published
2017

2. Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis

Author

Toshiaki Hanafusa, Yoshimitsu Doi, Takafumi Hosokawa, Shimon Ishida, Kazushi Yamane, Kiichi Unoda, Hideto Nakajima, and Fumiharu Kimura

Subjects
Encephalomyelitis, Autoimmune, Experimental, Time Factors, Encephalomyelitis, Peroxisome Proliferator-Activated Receptors, Immunology, Administration, Oral, Peroxisome proliferator-activated receptor, Pharmacology, complex mixtures, Neuroprotection, Statistics, Nonparametric, Interferon-gamma, Mice, medicine, Animals, Immunology and Allergy, RNA, Messenger, Receptor, health care economics and organizations, chemistry.chemical_classification, Interleukin-7, Experimental autoimmune encephalomyelitis, Cell Differentiation, social sciences, Peroxisome, medicine.disease, Eicosapentaenoic acid, Interleukin-10, Mice, Inbred C57BL, Disease Models, Animal, Eicosapentaenoic Acid, Neutrophil Infiltration, Neurology, chemistry, CD4 Antigens, Th17 Cells, Female, lipids (amino acids, peptides, and proteins), Neurology (clinical), geographic locations, Polyunsaturated fatty acid
Abstract

Eicosapentaenoic acid (EPA), one of the n-3 polyunsaturated fatty acids, is a neuroprotective lipid with anti-inflammatory properties. We investigated the possible therapeutic effect of EPA on experimental autoimmune encephalomyelitis (EAE). EAE mice were fed a diet with or without EPA. The clinical EAE scores of the EPA-fed mice were significantly lower than those of the non-EPA mice. In the EPA-treated mice, IFN-γ and IL-17 productions were remarkably inhibited and the expression levels of peroxisome proliferator-activated receptors were significantly enhanced in the CNS-infiltrating CD4T cells. Thus EPA shows promise as a potential new therapeutic agent against multiple sclerosis.

Published
2013
Full Text
View/download PDF

3. Increased serum matrix metalloproteinase-9 in neuromyelitis optica: implication of disruption of blood-brain barrier

Author

Hideto Nakajima, Toshiaki Hanafusa, Yoshimitsu Doi, Masakazu Sugino, Takafumi Hosokawa, Fumiharu Kimura, and Toshiyuki Takahashi

Subjects
Adult, Male, Immunology, Serum albumin, Blood–brain barrier, Pathogenesis, Young Adult, medicine, Immunology and Allergy, Humans, Interleukin 8, Neuromyelitis optica, Tissue Inhibitor of Metalloproteinase-1, biology, business.industry, Multiple sclerosis, Neuromyelitis Optica, Matrix metalloproteinase 9, Middle Aged, Pathogenicity, medicine.disease, medicine.anatomical_structure, Neurology, Matrix Metalloproteinase 9, Blood-Brain Barrier, biology.protein, Female, Neurology (clinical), business, Biomarkers
Abstract

Matrix metalloproteinase-9 (MMP-9) plays an important role in some neuroinflammatory diseases through the blood-brain barrier (BBB) disruption. To investigate the pathogenicity of MMP-9 in neuromyelitis optica (NMO), serum and CSF MMP-9 concentrations were measured in 13 NMO and 15 multiple sclerosis (MS) patients and 14 healthy controls, and correlated with clinical and laboratorial parameters. Serum MMP-9 concentrations were significantly higher in NMO than MS and controls, and correlated with EDSS score, CSF/serum albumin ratio, and CSF IL-8 concentrations. Our results indicate that MMP-9, promoted by elevated IL-8 activation, plays a crucial role in the pathogenesis of NMO through the BBB disruption.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results